Exploring Immunotherapy Combinations in Endometrial Cancer

home / insights / exploring-immunotherapy-combinations-in-endometrial-cancer

Experts in gynecologic oncology review key advances in treating advanced endometrial cancer and the promise of combination immunotherapy-based regimens.

EP. 1: Role of Combination I/O in Advanced Endometrial Cancer (EC)

Shannon N. Westin, MD, MPH, The University of Texas MD Anderson Cancer Center;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

April 14th 2021

Shannon N. Westin, MD, MPH, FACOG, discusses the rationale for the use of combination immunotherapy for advanced and recurrent endometrial cancer.

EP. 2: Phase 3 KEYNOTE-775 Trial in Advanced Endometrial Cancer

Shannon N. Westin, MD, MPH, FACOG;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

May 4th 2021

Vicky Makker, MD, reviews the trial design and efficacy data for the open-label, randomized phase 3 KEYNOTE-775/Study 309 in patients with advanced endometrial cancer.

EP. 3: Safety Results From KEYNOTE-775 Trial in Advanced EC

Shannon N. Westin, MD, MPH, FACOG;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

May 4th 2021

Vicky Makker, MD, reviews the safety profile of lenvatinib-pembrolizumab in advanced endometrial cancer from the phase 3 KEYNOTE-775/Study 309 trial and the management of common adverse events.

EP. 4: Impact of Lenvatinib-Pembrolizumab on Clinical Practice in Advanced EC

Shannon N. Westin, MD, MPH, FACOG;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

May 12th 2021

Vicky Makker, MD, and Shannon N. Westin, MD, MPH, FACOG, discuss their experiences using lenvatinib-pembrolizumab therapy for advanced endometrial cancer.

EP. 5: Patient Selection for Lenvatinib-Pembrolizumab for Advanced EC

Shannon N. Westin, MD, MPH, FACOG;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

May 12th 2021

Experts in gynecologic oncology share insights on patient selection for lenvatinib-pembrolizumab in advanced endometrial cancer and discuss therapeutic sequencing through multiple lines of therapy.

EP. 6: Emerging Data From Ongoing IO Combination Trials in EC

Shannon N. Westin, MD, MPH, FACOG;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

May 19th 2021

Shannon N. Westin, MD, MPH, FACOG, and Vicky Makker, MD, comment on data from ongoing clinical trials presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer for the management of advanced endometrial cancer.